YOUNG HIGH RISK PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA INCLUDING BCL‐2/MYC DOUBLE HIT LYMPHOMAS BENEFIT FROM DOSE‐DENSE IMMUNOCHEMOTHERAPY WITH EARLY CNS PROPHYLAXIS. (12th June 2019) - Leppä, S.; Jørgensen, J.; Tierens, A.; Meriranta, L.; Østlie, I.; Brown, P.; Fagerli, U.; Larsen, T.S.; Mannisto, S.; Munksgaard, L.; Maisenhølder, M.; Vasala, K.; et al.